GREATER THAN 1-YEAR SURVIVAL BENEFIT FOR THE FITTEST PATIENTS (ECOG PS 0)8

Post-hoc analysis of survival by performance status
Median overall survival (OS) by KPS subgroups | KPS 90-100: ABRAXANE + gemcitabine (9.7 months, 8.71-10.91) vs gemcitabine alone (7.9 months, 6.97-9.03), HR (95% CI) 0.75 (0.62-0.92); KPS 70-80: ABRAXANE +
gemcitabine (7.6 months, 6.44-8.38) vs gemcitabine alone (4.3 months, 3.81-5.72), HR (95% CI) 0.61 (0.48-0.78) Median overall survival (OS) by KPS subgroups | KPS 90-100: ABRAXANE + gemcitabine (9.7 months, 8.71-10.91) vs gemcitabine alone (7.9 months, 6.97-9.03), HR (95% CI) 0.75 (0.62-0.92); KPS 70-80: ABRAXANE +
gemcitabine (7.6 months, 6.44-8.38) vs gemcitabine alone (4.3 months, 3.81-5.72), HR (95% CI) 0.61 (0.48-0.78)
  • ECOG PS 0 to 1 (KPS 90-100)
    9.7 months (n=248; 95% CI: 8.71-10.91) with ABRAXANE + gemcitabine vs 7.9 months (n=268; 95% CI: 6.97-9.03) with gemcitabine (HR=0.75 [95% CI: 0.62-0.92])
  • ECOG PS 1 to 2 (KPS 70-80)
    7.6 months (n=179; 95% CI: 6.44-8.38) with ABRAXANE + gemcitabine vs 4.3 months (n=161; 95% CI: 3.81-5.72) with gemcitabine (HR=0.61 [95% CI: 0.48-0.78])
Analysis limitations: An exploratory analysis should not be interpreted to determine a treatment difference between arms in these selected subgroups because of insufficient sample size and a higher probability of making a false-positive finding.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL